advertising
-
1
Kazmi B, Inglefield CJ, Lewis MP: Autologous cell therapy: current treatments and future prospects. Wounds 21: 234, 2009.
-
2
Snyder RJ: Treatment of nonhealing ulcers with allografts. Clin Dermatol 23: 388, 2005.
-
3
Tavis MJ, Thornton J, Danet R, et al.: Current status of skin substitutes. Surg Clin North Am 58: 1233, 1978.
-
4
ASTM International. Standard guide for classification of cellular and/or tissue-based products (CTPs) for skin wounds: designation F3163-16. 2016. Available at: https://www.astm.org/f3163-16.html.
-
5
Serena TE, Kushnir I, Kushnir A, et al.: The safety of an autologous whole blood clot product applied to full thickness dermal wounds in a porcine model for up to 18 days. Chronic Wound Care Manag Res 6: 39, 2019.
-
6
Snyder RJ, Kasper MA, Patel K, et al.: Safety and efficacy of an autologous blood clot product in the management of Texas 1A or 2A neuropathic diabetic foot ulcers: a prospective, multicenter, open label pilot study. Wounds 30: 84, 2018.
-
7
Donner B, Patel K, Serena TE: Analysis of three prospective, open-label, clinical trials with autologous blood clot in chronic wounds. Poster presented at: Symposium on Advanced Wound Care Spring, Charlotte, NC, 2019.
-
8
Periayah MH, Halim AS, Mat Saad AZ: Mechanism action of platelets and crucial blood coagulation pathways in hemostasis. Int J Hematol Oncol Stem Cell Res 11: 319, 2017.
-
9
Wong VW, Gurtner GC, Longaker MT: Wound healing: a paradigm for regeneration. Mayo Clin Proc 88: 1022, 2013.
-
10
Bearer EL, Prakash JM, Li Z: Actin dynamics in platelets. Int Rev Cytol 217: 137, 2002.
-
11
Franco AT, Corken A, Ware J: Platelets at the interface of thrombosis, inflammation, and cancer. Blood 126: 582, 2015.
-
12
Yun S-H, Sim E-H, Goh R-Y, et al.: Platelet activation: the mechanisms and potential biomarkers. Biomed Res Int 2016: 9060143, 2016.
-
13
Bodnar RJ: Epidermal growth factor and epidermal growth factor receptor: the yin and yang in the treatment of cutaneous wounds and cancer. Adv Wound Care 2: 24, 2013.
-
14
Laurens N, Koolwijk P, De Maat MPM: Fibrin structure and wound healing. J Thromb Haemost 4: 932, 2006.
-
15
Nerem RM: Cell-based therapies: from basic biology to replacement, repair, and regeneration. Biomaterials 28: 5074, 2007.
-
16
Falanga V: The chronic wound: impaired healing and solutions in the context of wound bed preparation. Blood Cells Dis 32: 88, 2004.
-
17
Fu X, Liu G, Halim A, et al.: Mesenchymal stem cell migration and tissue repair. Cells 8: 784, 2019.
-
18
Kobayashi E, Flückiger L, Fujioka-Kobayashi M, et al.: Comparative release of growth factors from PRP, PRF, and advanced-PRF. Clin Oral Investig 20: 2353, 2016.
-
19
Zhang Z, Li X, Zhao J, et al.: Effect of autogenous growth factors released from platelet concentrates on the osteogenic differentiation of periodontal ligament fibroblasts: a comparative study. PeerJ 7: e7984, 2019.
-
20
Guo S, Dipietro LA: Factors affecting wound healing. J Dent Res 89: 219, 2010.
-
21
Eming SA, Martin P, Tomic-Canic M: Wound repair and regeneration: mechanisms, signaling, and translation. Sci Transl Med 6: 265r6, 2014.
-
22
Anitua E, Pino A: The management of postsurgical wound complications with plasma rich in growth factors. Adv Skin Wound Care 33: 202, 2020.
-
23
Wahab N, Lapucha M, Chauhan C: Initial experience using autologous blood clot to promote closure in chronic pressure ulceration. Poster presented at: Symposium for the Advancement of Wound Care, 2020.
-
24
Schultz GS, Davidson JM, Kirsner RS, et al.: Dynamic reciprocity in the wound microenvironment. Wound Repair Regen 19: 134, 2011.
-
25
Cullen B, Smith R, McCulloch E, et al.: Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen 10: 16, 2002.
-
26
Ladwig GP, Robson MC, Liu R, et al.: Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen 10: 26, 2002.
-
27
Das A, Sinha M, Datta S, et al.: Monocyte and macrophage plasticity in tissue repair and regeneration. Am J Pathol 185: 2596, 2015.
-
28
Hesketh M, Sahin KB, West ZE, et al.: Macrophage phenotypes regulate scar formation and chronic wound healing. Int J Mol Sci 18: 1545, 2017.
-
29
Snyder RJ, Lantis J, Kirsner RS, et al.: Macrophages: a review of their role in wound healing and their therapeutic use. Wound Repair Regen 24: 613, 2016.
-
30
Sindrilaru A, Peters T, Wieschalka S, et al.: An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest 121: 985, 2011.
-
31
Krzyszczyk P, Schloss R, Palmer A, et al.: The role of macrophages in acute and chronic wound healing and interventions to promote pro-wound healing phenotypes. Front Physiol 9: 419, 2018.
-
32
Macrae FL, Duval C, Papareddy P, et al.: A fibrin biofilm covers blood clots and protects from microbial invasion. J Clin Invest 128: 3356, 2018.
-
33
Chen J, Li X, Li L, et al.: Coagulation factors VII, IX and X are effective antibacterial proteins against drug-resistant Gram-negative bacteria. Cell Res 29: 711, 2019.
-
Smith SA, Travers RJ, Morrissey JH: How it all starts: initiation of the clotting cascade. Crit Rev Biochem Mol Biol 50: 326, 2015.
Proposed Mechanism of Action of Topically Applied Autologous Blood Clot Tissue
A Quintessential Cellular and Tissue-Based Therapy
Search for other papers by Robert J. Snyder in
Current site
Google Scholar
PubMed
Search for other papers by Gregroy Schultz in
Current site
Google Scholar
PubMed
Search for other papers by Chinenye Wachuku in
Current site
Google Scholar
PubMed
Search for other papers by Arij M. Rashid in
Current site
Google Scholar
PubMed
Search for other papers by Joey Karim Ead in
Current site
Google Scholar
PubMed
Background: Chronic wounds, especially in patients with diabetes, often represent clinical challenges. Recently, the use of a topically applied blood clot has garnered significant interest. This stromal matrix contains viable cells that are autologous, biocompatible, biological, and consistent with a metabolically active scaffold. It has been shown to be safe, effective, and cost-efficient. However, the mechanism of action of this modality remains elusive. We sought to identify a potential mechanism of action of an autologous blood clot.
Methods: Review of clinical and scientific literature hypothesizes on how autologous blood clots may stimulate healing and facilitate the movement of critical substrates while lowering bioburden and fostering angiogenesis.
Results: Blood serves as a carrier for many components: red blood cells, white blood cells, platelets, proteins, clotting factors, minerals, electrolytes, and dissolved gasses. In response to tissue injury, the hemostatic mechanism uses a host of vascular and extravascular responses initiating primary, secondary, and tertiary hemostasis. The scaffold created by the autologous blood clot tissue provides a medium in which the body can transform the wound from a nonhealing chronic condition into a healing acute condition. The autologous blood clot tissue also creates a protective setting for the body to use its own mechanisms to promote wound healing in an organized manner. This transient scaffold recruits surrounding fibroblasts and promotes cell ingrowth to foster granulation tissue remodeling. Cells in this matrix sense not only soluble factors but also their physical environments. This well-orchestrated mechanism includes signals from soluble molecules, from the substrate/matrix to which the cell is adherent, from the mechanical or physical forces acting on it, and from contact with other cells. Topically applied autologous blood clot tissue can lower bacterial bioburden while stimulating angiogenesis and fostering the movement of keratinocytes and fibroblasts.
Conclusions: Topically applied autologous blood clot tissue is a formidable cellular and tissue-based therapy that has been shown to be safe and effective. Although the central component of this therapy is blood, the autologous clot tissue creates a scaffold that performs as a biological delivery system that functions to control the release of growth factors and cytokines over several days.
advertising
